IOTest®3
FMC7-FITC / CD23-PE / CD19-ECD

REF A07709
25 tests; 0.5 mL
20 µL / test

BECKMAN COULTER™

IOTest 3
Conjugated Antibodies

IVD CE

ENGLISH	Specifications of constituent 1	Specifications of constituent 2	Specifications of constituent 3
Specificity	FMC7	CD23	CD19
Clone	FMC7	9P25	J4.119
Hybridoma	P3-NS1-1-Ag4-1 x Balb/c	NS1 x Balb/c	NS1 x Balb/c
Immunogen	Human B HRIK lymphoblastoid cells	EBV modified lymphoblastoid cells	Lymphoma cells SKLY18
Immunoglobulin	IgM	IgG1	IgG1
Species	Mouse	Mouse	Mouse
Source	Ascites	Ascites	Ascites
Purification	Chromatography	Chromatography on Protein A	Chromatography on Protein A
Fluorochrome	Fluorescein isothiocyanate (FITC)	R Phycoerythrin (PE)	R Phycoerythrin-Texas Red®-X (ECD™)
λ excitation	488 nm	488 nm	488 nm
Emission peak	525 nm	575 nm	613 nm
Buffer	Buffer (PBS pH 7.2) plus 2 mg / mL BSA and 0.1% NaN_3		

USE
This fluorochrome-conjugated antibody mixture is suitable for multiparametric analysis using flow cytometry. It permits the detection of the expression of FMC7, CD23 and CD19 antigens in leucocytes.

PRINCIPLE
This test is based on the ability of specific monoclonal antibodies to bind to the antigenic determinants expressed by leucocytes.
Specific staining of the leucocytes is performed by incubating the sample with the IOTest 3 reagent. The red cells are then removed by lysis and the leucocytes, which are unaffected by this process, are analyzed by flow cytometry.
The flow cytometer analyzes light diffusion and the fluorescence of cells. It makes possible the localization of cells within the electronic window defined on a histogram, which correlates the orthogonal diffusion of light ("Side Scatter" or SS) with the fluorescence of the ECD corresponding to CD19 staining. Other histograms combining two of the different parameters available on the cytometer, are also used in the electronic gating stage. The cell population thus gated is subdivided into sub-populations, using the two other fluorescences.
In this way, the positively-stained cells are distinguished from the unstained cells. The results are expressed as a percentage of fluorescent cells in relation to all the events acquired by the electronic gating.

EXAMPLES OF CLINICAL APPLICATIONS
The simultaneous analysis of FMC7, CD23 and CD19 antigens is useful for the characterization of chronic B lymphoid leukaemias and small cell lymphomas which are $FMC7^{-}CD23^{+}CD19^{+}$ and $FMC7^{dim}CD23^{+}CD19^{+}$, respectively (1). Mantle-cell lymphomas and hairy-cell leukaemias, however, are $FMC7^{+}CD23^{-}CD19^{+}$ (2 - 5).

STORAGE AND STABILITY
The conjugated liquid forms must be kept at between 2 and 8°C and protected from light, before and after the vial has been opened.
Stability of closed vial: see expiry date on vial.
Stability of opened vial: the reagent is stable for 90 days.

PRECAUTIONS
1. Do not use the reagent beyond the expiry date.
2. Do not freeze.
3. Let it come to room temperature (18-25°C) before use.
4. Minimize exposure to light.
5. Avoid microbial contamination of the reagents, or false results may occur.
6. Antibody solutions containing sodium azide (NaN_3) should be handled with care. Do not take internally and avoid all contact with the skin, mucosa and eyes.
   Furthermore, in an acid medium, sodium azide can form the potentially dangerous hydrazoic acid. If it needs to be disposed of, it is recommended that the reagent be diluted in a large volume of water before pouring it into the drainage system so as to avoid the accumulation of sodium azide in metal pipes and to prevent the risk of explosion.
7. All blood samples must be considered as potentially infectious and must be handled with care (in particular: the wearing of protective gloves, gowns and goggles).
8. Never pipette by mouth and avoid all contact of the samples with the skin, mucosa and eyes.
9. Blood tubes and disposable material used for handling should be disposed of in ad hoc containers intended for incineration.

SPECIMENS
Venous blood or bone marrow samples must be taken using sterile tubes containing an EDTA salt as the anticoagulant. The use of other anticoagulants is not recommended.
The samples should be kept at room temperature (18-25°C) and not shaken. The samples should be homogenized by gentle agitation prior to taking the test sample.
The samples must be analyzed within 24 hours of taking them.

METHODOLOGY
NECESSARY MATERIAL NOT SUPPLIED
- Sampling tubes and material necessary for sampling.
- Automatic pipettes with disposable tips for 20, 100 and 500 µL.
- Plastic haemolysis tubes.
- Calibration beads: Flow-Set™ Fluorospheres (Ref. 6607007).
- To obtain optimal results, the following reagents are recommended:
  - Lysing reagent: IOTest 3 Lysis Solution (Ref. A07799).
  - Fixation reagent: IOTest 3 Fixative Solution (Ref. A07800).
  - One of the following IOTest 3 negative controls:
    Neg.Ctrl.-FITC /Neg.Ctrl.-PE/CD19-ECD (Ref. A07730) or
    Neg.Ctrl.-FITC /Neg.Ctrl.-PE/Neg.Ctrl.-ECD (Ref. A07732).
- Buffer (PBS: 0.01 M sodium phosphate; 0.145 M sodium chloride; pH 7.2).
- Centrifuge.
- Automatic agitator (Vortex type).
- Flow cytometer.

PROCEDURE
For each sample analyzed, in addition to the test tube, one control tube is required in which the cells are mixed with the selected IOTest 3 negative control (Ref. A07730 or A07732).
1. Add 20 µL of specific IOTest 3 conjugated antibodies to each test tube, and 20 µL of the appropriate negative control to each control tube.
2. Add 100 µL of the test sample to the 2 tubes. Vortex the tubes slowly.
3. Incubate for 15 to 20 minutes at room temperature (18-25°C), protected from light.
4. Then perform, if necessary, lysis of the red cells by adding 2 mL of IOTest 3 Lysis Solution (Ref. A07799) at its working concentration (1X). Vortex immediately and incubate for 10 minutes at room temperature, protected from light. If the sample does not contain red cells, add 2 mL of PBS.
5. Centrifuge for 5 minutes at 300 x g at room temperature.
6. Remove the supernatant by aspiration.
7. Resuspend the cell pellet using 3 mL of PBS.
8. Repeat stage 5.
9. Remove the supernatant by aspiration and resuspend the cell pellet using:
   - 0.5 mL or 1 mL of IOTest 3 Fixative Solution (Ref. A07800) at its working concentration (1X), if the preparations are to be kept for more than 2 hours and for less than 24 hours,
   - 0.5 mL or 1 mL of PBS without formaldehyde, if the preparations are to be analyzed within 2 hours.

Note: In all cases, keep the preparations between 2 and 8°C and protected from light.

PERFORMANCE
SPECIFICITY
The molecule recognized by the monoclonal antibody (mAb) FMC7 is a transmembrane glycoprotein with a molecular weight of 104 kDa (6, 7).
The mAb 9P25 was assigned to CD23 during the 6th HLDA Workshop on Human Leucocyte Differentiation Antigens, held in Kobe, Japan, in 1996 (WS Code: CD23.1, Section B) (8, 9).
The mAb J4.119 was assigned to CD19 during the 3rd HLDA Workshop held in Oxford, England, in 1986 (WS Code: B191, Section B) (10).

LINEARITY
To test the linearity of staining for the specificities of this reagent, a positive cell line and a negative cell line were mixed in different proportions with a constant final number of cells,

A07709EN_A 2003-07-23
AC-03-0611

so that the positive line/negative line ratio of the mixture ranged from 0 to 100%.
Aliquots were stained using the procedure described above and linear regression between the expected values and the observed values was calculated. The parameters of the equation of the linear regression may be used to determine the coefficient of linearity as well as the range of measurement for each specificity.

Specificity	Linear regression	Linearity (R^2)	Range (%)
FMC7	Y = 0.93 X + 3.42	0.998	4 - 95
CD23	Y = 0.97 X + 1.98	0.999	3 - 98
CD19	Y = 0.97 X + 1.58	0.999	3 - 98

EXPECTED VALUES

Each laboratory must compile a list of reference values based upon a group of healthy donors from the local population. This must be done by taking age, sex and ethnic group into account, as well as any other potential regional differences.
In our laboratories, samples of the whole blood of 50 healthy adults were treated using the reagent described above. The mean values of the results obtained in the leucocyte sub-populations of interest in these 50 donors are shown in the tables below:

Lymphocytes	Number	Mean (%)	SD	CV (%)
FMC7+	50	9.29	5.18	56
CD23+	50	7.55	4.18	55
CD19+	50	9.74	4.77	49

Monocytes	Number	Mean (%)	SD	CV (%)
CD23+	50	6.43	6.02	94

INTRA-LABORATORY REPRODUCIBILITY

On the same day and using the same cytometer, 12 measurements of the percentage of positive target cells (lymphocytes) were carried out. The results obtained are summarized in the following table:

Lymphocytes	Number	Mean (%)	SD	CV (%)
FMC7+	12	11.49	1.16	10.12
CD23+	12	7.03	0.70	10.02
CD19+	12	12.04	1.22	10.15

INTER-LABORATORY REPRODUCIBILITY

On the same day and on the same positive target cells (lymphocytes), 12 measurements of the percentage of positive cells were carried out by two technicians and the preparations analyzed using two different cytometers. The results obtained are summarized in the following tables:

Cytometer n°1:

Lymphocytes	Number	Mean (%)	SD	CV (%)
FMC7+	12	11.49	1.16	10.12
CD23+	12	7.03	0.70	10.02
CD19+	12	12.04	1.22	10.15

Cytometer n°2:

Lymphocytes	Number	Mean (%)	SD	CV (%)
FMC7+	12	8.59	0.98	11.4
CD23+	12	5.68	0.65	11.5
CD19+	12	9.14	1.05	11.5

LIMITATIONS OF THE TECHNIQUE

1. Flow cytometry may produce false results if the cytometer has not been aligned perfectly, if fluorescence leaks have not been correctly compensated for and if the regions have not been carefully positioned.
2. It is preferable to use a lysis technique with washing as this reagent has not been optimized for "without washing" lysis techniques.
3. Accurate and reproducible results will be obtained as long as the procedures used are in accordance with the technical insert leaflet and compatible with good laboratory practices.
4. The antibodies of this reagent are calibrated so as to offer the best specific signal/non-specific signal ratio. Therefore, it is important to adhere to the reagent volume/number of cells ratio in every test.
5. In the case of a hyperleucocytosis, dilute the blood in PBS so as to obtain a value of approximately 5 x 10^9 leucocytes/L.
6. In certain disease states, such as severe renal failure or haemoglobinopathies, lysis of red cells may be slow, incomplete or even impossible. In this case, it is recommended to isolate mononucleated cells using a density gradient (Ficoll, for example) prior to staining.

MISCELLANEOUS

See the Appendix for examples and references.

TRADEMARKS

MANUFACTURED BY:

IMMUNOTECH S.A.
a Beckman Coulter Company
130, avenue de Lattre de Tassigny
B.P. 177 – 13276 Marseille Cedex 9
France
Customer Services: (33) 4 91 17 27 27

www.beckmancoulter.com

APPENDIX TO REF A07709

EXAMPLES

The 4 diagrams below are biparametric Contour Plot representations (Side Scatter *versus* Fluorescence Intensity or Fluorescence Intensity *versus* Fluorescence Intensity) of a Mantle Cell Lymphoma (MCL) specimen (peripheral blood). Staining is with FMC7-FITC / CD23-PE / CD19-ECD Conjugated Antibodies (Ref. A07709). Lysis and fixation are with IOTest 3 Lysing Solution (Ref. A07799) and IOTest 3 Fixative Solution (Ref. A07800) respectively. All acquired events are shown on Figure 1. Region A (CD19 positive cluster) defines the gating strategy used on this example. Gated events are shown in Figure 2, 3 and 4.

Acquisition is with a COULTER® EPICS® XL™ flow cytometer equipped with System II™ Software. Analysis is with EXPO™ Cytometer Software (Ref. 6605434).



Figure 1



Figure 2



Figure 3



Figure 4

REFERENCES

1. Braylan, R C., Orfao, A., Borowitz, M J., Davis, B H., “Optimal number of reagents required to evaluate hematolymphoid neoplasias: results of an international consensus meeting” 2001, Cytometry, 46, 23-27.
2. Borowitz, M.J., Bray, R., Gascoyne, R., Melnick, S., Parker, J.W., Picker, L., Stetler-Stevenson, M., "U.S. Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: Data analysis and interpretation", 1997, Cytometry, 30, 236-244.
3. Rothe, G., Schmitz, G., Adorf, D., Barlage, S., Gramatzki, M., Höffkes, H.G., Janossy, G., Knüchel, R., Ludwig, W.D., Nebe, T, Nerl, C., Orfao, A., Serke, S., Sonnen, R., Tichelli, A., Wörmann, B., "Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies", 1996, Leukemia, 10, 877-895.
4. Kilo, M.N., Dorfman, D.M., "The utility of flow cytometric immunophenotypic analysis in the distinction of small lymphocytic lymphoma / chronic lymphocytic leukemia from mantle cell lymphoma", 1996, Am. J. Clin. Pathol., 105, 451-457
5. DiGiuseppe, J.A., Borowitz, M.J., "Clinical utility of flow cytometry in the chronic lymphoid leukemias", 1998, Seminars in Oncology, 1, 25, 6-10.
6. Zola, H., Moore, H.A., Hohmann, A., Hunter, I.K., Nikoloutsopoulos, A., Bradley, J., "The antigen of mature human B cells detected by the monoclonal antibody FMC7: Studies on the nature of the antigen and modulation of its expression", 1984, J. Immunol., 1, 133, 321-326.
7. Ferro, L.M., Zola, H., "Modulation of expression of the antigen identified by FMC7 upon human B-lymphocyte activation: Evidence for differences between activation *in vivo* and *in vitro*", 1990, Immunology, 69, 373-378.
8. Bonnefoy, J.Y., Aubry, J.P., Peronne, C., Wijdenes, J., Banchereau, J., "Production and characterization of a monoclonal antibody specific for the human lymphocyte low affinity receptor for IgE: CD23 is a low affinity receptor for IgE", 1987, J. Immunol., 9, 138, 2970-2978.
9. Goff, L.K., Armitage, R.J., Beverley, P.C.L., "Characterization of two CD23 monoclonal antibodies with reactivity distinct from other antibodies within this cluster of differentiation", 1988, Immunology, 65, 213-220.
10. Tedder, F., Isaacs, C.M., Penta, A., "Cloning and structure of CD19, a member of the immunoglobulin superfamily. Use of transfected cells to examine the Workshop antibodies", 1989, Leucocyte Typing IV, White Cell Differentiation Antigens. W. Knapp, et al., Eds., Oxford University Press, 36-38.